Evolocumab

The White House announced it has signed nine new agreements with pharmaceutical companies Amgen , Bristol Myers Squibb , Boehringer Ingelheim , Genentech , Gilead Sciences , GSK , Merck , Novartis and Sanofi to offer medications through TrumpRx at discounted rates. According to the White House, Boehringer Ingelheim's Jentadeuto for type 2 diabetes will be listed for $55 for U.S. patients, Bristol Myers Squibb's Reyataz for HIV will be $217, Genentech's Xofluza flu medication will be $50, and Amgen's Repatha, used to lower high cholesterol, will be offered through TrumpRx for $239. TrumpRx will also offer Gilead Sciences' Epclusa hepatitis C medication for $2,425, Merck's Januvia for diabetes at $100 and Novartis' Mayzent for multiple sclerosis for $1,137, and Sanofi will reduce the price of its prescription blood thinner, Plavix, to $16. Sanofi will also list its insulin products on TrumpRx at $35 per month’s supply, and GSK will reduce the prices of its inhaler portfolio, including its asthma inhaler Advair Diskus 500/50, to $89. The pharma giants are also collectively investing at least $150 billion in U.S. manufacturing and donating active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve, which aims to increase the U.S. supply of such products in the event of an emergency and reduce America's reliance on foreign nations. THE LARGER TREND Earlier this month, Boehringer Ingelheim announced it had signed an agreement with the Trump administration that allows the pharma giant to be excluded from potential Section 232 tariffs. The pharma giant plans to spend $10 billion to expand its research and development and manufacturing operations in the U.S. through 2028, including $1 billion for capital expenditures. The agreement means the bulk of Boehringer's medications for U.S. patients will be produced in the United States. In November, the White House announced it signed agreements with Eli Lilly and Company and Novo Nordisk to offer GLP-1s Zepbound, orforglipron, Ozempic and Wegovy through TrumpRx at a discounted rate. TrumpRx launched in September and announced it brokered a deal with Pfizer to offer some of the pharma giant's medications at a discount through the prescription digital marketplace. That deal also allowed Pfizer to avoid U.S. tariffs on overseas-made drugs for three years by offering its medications through TrumpRx.

Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing THOUSAND OAKS, Calif. , Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while reinforcing Amgen's long-standing commitment to innovation. The action satisfies the components outlined in President Trump's July 31 letter, including the Administration's Most Favored Nation pricing requests. Additional details remain confidential. "The U.S. leads the world in biopharmaceutical innovation, and we look forward to continued engagement with the U.S. government to see that this innovation is appropriately supported globally," said Robert A. Bradway, chairman and chief executive officer at Amgen. Amgen will expand its direct-to-patient program, AmgenNow™ , to include Aimovig ® (erenumab-aooe) and Amjevita ® (adalimumab-atto). Both will be available at a discounted monthly price of $299, nearly 60% and 80% lower than their current U.S. list prices, respectively. In October 2025 , the company launched AmgenNow and made Repatha ® (evolocumab) available to American patients at a monthly price of $239, nearly 60% below its current U.S. list price. The program is open to all eligible patients, including those who are uninsured, enrolled in high-deductible health plans or prefer to pay with cash or out of pocket. All three medicines will also be offered through TrumpRx.gov. Since 2018, Amgen has invested more than $40 billion in manufacturing and research and development, building on its leadership in innovation and state-of-the-art operations in the U.S. These investments were facilitated by the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. The enactment of pro-growth tax policies in the TCJA, reinforced by the One Big Beautiful Bill Act of 2025, further enabled Amgen to invest domestically in science and manufacturing. This year, Amgen announced an additional $2.5 billion in U.S. manufacturing capital investments, including expansions of $900 million in Ohio and $1 billion in North Carolina . In recognition of these continued investments, Amgen will receive relief from industry-specific tariffs for the next three years. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook, 609-251-1407 (media) Casey Capparelli, 805-447-1746 (investors) View original content to download multimedia: SOURCE Amgen